WebDec 9, 2024 · On December 1, 2024, FDA approved Rezlidhea (Olutasidenib) to treat adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible mutation.Olutasidenib (FT2102) is a highly potent, orally active, brain-penetrant, and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1). WebFebruary 22 2024, Shanghai—Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) today announced that ABSK121, a next-generation small molecule FGFR inhibitor overcoming FGFR resistance mutations, has obtained clinical trial approval from the National Medical Products Administration (“NMPA”) of the People’s Republic of China, and ...
Pemigatinib: Hot topics behind the first approval of a targeted …
WebMar 30, 2024 · The FDA has accepted Taiho Oncology’s investigational therapy futibatinib for priority review, the company announced Wednesday. The oral, selective small molecule inhibitor of FGFR1, 2, 3, and 4 ... WebApr 12, 2024 · The FDA has granted accelerated approval to erdafitinib (Balversa) for the treatment of adult patients with locally advanced or metastatic bladder cancer with fibroblast growth factor receptor... small cheap boxes with lids
FDA Approved Fibroblast Growth Factor Receptor FGFR
WebApr 14, 2024 · Abstract. High-risk neuroblastoma (NB) has a poor prognosis despite multimodal treatment. To improve survival and minimise treatment side-effects, research has focused on developing more effective therapeutic strategies. Anaplastic lymphoma kinase (ALK) is a promising druggable target as its expression rapidly decreases in healthy … WebThe FDA simultaneously approved a companion diagnostic for use with BALVERSA, the QIAGEN therascreen ® FGFR RGQ Reverse-transcription (RT)-polymerase chain … WebGeneric Name Erdafitinib DrugBank Accession Number DB12147 Background. In early April of 2024, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, … some tap offerings in brief